<DOC>
	<DOCNO>NCT01763827</DOCNO>
	<brief_summary>The primary objective evaluate effect 12 week evolocumab subcutaneous ( SC ) monotherapy every 2 week ( Q2W ) monthly ( QM ) , compare placebo ezetimibe , percent change baseline low-density lipoprotein cholesterol ( LDL-C ) adults 10-year Framingham risk score 10 % less .</brief_summary>
	<brief_title>Monoclonal Antibody Against PCSK9 Reduce Elevated LDL-C Subjects Currently Not Receiving Drug Therapy Easing Lipid Levels-2</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Male female ≥ 18 ≤ 80 year age National Cholesterol Education Program Adult Treatment Panel III ( NCEP ATP III ) Framingham risk score 10 % less Fasting LDLC ≥ 100 mg/dL ( 2.6 mmol/L ) &lt; 190 mg/dL Fasting triglycerides ≤ 400 mg/dL ( 4.5 mmol/L ) History coronary heart disease New York Heart Association ( NYHA ) III IV heart failure Uncontrolled cardiac arrhythmia Uncontrolled hypertension Diabetes mellitus ( Type 1 diabetes , poorly control type 2 diabetes ) Uncontrolled hypothyroidism hyperthyroidism</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>High cholesterol , Treatment high cholesterol , Lowering cholesterol , Lowering high cholesterol , Hypercholesterolemia</keyword>
</DOC>